105 related articles for article (PubMed ID: 29098396)
61. Treatment adoption and relative effectiveness of aromatase inhibitors compared to tamoxifen in early breast cancer: A multi-institutional observational study.
Ferreira AR; Palha A; Correia L; Filipe P; Rodrigues V; Miranda A; André R; Fernandes J; Gouveia J; Passos-Coelho JL; Moreira A; Brito M; Ribeiro J; Metzger-Filho O; Lin NU; Costa L; Vaz-Luis I
Breast; 2018 Feb; 37():107-113. PubMed ID: 29131988
[TBL] [Abstract][Full Text] [Related]
62. Hormone Receptor-Positive Breast Cancer Has a Worse Prognosis in Male Than in Female Patients.
Li X; Yang J; Krishnamurti U; Huo L; Ward KC; O'Regan R; Peng L
Clin Breast Cancer; 2017 Aug; 17(5):356-366. PubMed ID: 28576631
[TBL] [Abstract][Full Text] [Related]
63. Controversies in clinicopathological characteristics and treatment strategies of male breast cancer: A review of the literature.
Losurdo A; Rota S; Gullo G; Masci G; Torrisi R; Bottai G; Zuradelli M; Gatzemeier W; Santoro A
Crit Rev Oncol Hematol; 2017 May; 113():283-291. PubMed ID: 28427518
[TBL] [Abstract][Full Text] [Related]
64. Moderate HER2 expression as a prognostic factor in hormone receptor positive breast cancer.
Eggemann H; Ignatov T; Burger E; Kantelhardt EJ; Fettke F; Thomssen C; Costa SD; Ignatov A
Endocr Relat Cancer; 2015 Oct; 22(5):725-33. PubMed ID: 26187126
[TBL] [Abstract][Full Text] [Related]
65. Adjuvant therapy with tamoxifen compared to aromatase inhibitors for 257 male breast cancer patients.
Eggemann H; Ignatov A; Smith BJ; Altmann U; von Minckwitz G; Röhl FW; Jahn M; Costa SD
Breast Cancer Res Treat; 2013 Jan; 137(2):465-70. PubMed ID: 23224235
[TBL] [Abstract][Full Text] [Related]
66. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.
von Elm E; Altman DG; Egger M; Pocock SJ; Gøtzsche PC; Vandenbroucke JP;
Lancet; 2007 Oct; 370(9596):1453-7. PubMed ID: 18064739
[TBL] [Abstract][Full Text] [Related]
67. Is male breast cancer similar or different than female breast cancer?
Anderson WF; Althuis MD; Brinton LA; Devesa SS
Breast Cancer Res Treat; 2004 Jan; 83(1):77-86. PubMed ID: 14997057
[TBL] [Abstract][Full Text] [Related]
68. Male breast cancer.
Volm MD
Curr Treat Options Oncol; 2003 Apr; 4(2):159-64. PubMed ID: 12594942
[TBL] [Abstract][Full Text] [Related]
69. Male breast carcinoma: a review of 229 patients who presented to the Princess Margaret Hospital during 40 years: 1955-1996.
Goss PE; Reid C; Pintilie M; Lim R; Miller N
Cancer; 1999 Feb; 85(3):629-39. PubMed ID: 10091736
[TBL] [Abstract][Full Text] [Related]
70. Effect of long-term treatment with aromatase inhibitor on testicular function of adult male bonnet monkeys (M. radiata).
Shetty G; Krishnamurthy H; Krishnamurthy HN; Bhatnagar AS; Moudgal NR
Steroids; 1998; 63(7-8):414-20. PubMed ID: 9654648
[TBL] [Abstract][Full Text] [Related]
71. Sex differences in androgen-regulated expression of cytochrome P450 aromatase in the rat brain.
Roselli CE; Resko JA
J Steroid Biochem Mol Biol; 1997 Apr; 61(3-6):365-74. PubMed ID: 9365212
[TBL] [Abstract][Full Text] [Related]
72. Adjuvant tamoxifen for male breast cancer (MBC).
Ribeiro G; Swindell R
Br J Cancer; 1992 Feb; 65(2):252-4. PubMed ID: 1739625
[TBL] [Abstract][Full Text] [Related]
73. Survival benefit of tamoxifen and aromatase inhibitor in male and female breast cancer.
Eggemann H; Altmann U; Costa SD; Ignatov A
J Cancer Res Clin Oncol; 2018 Feb; 144(2):337-341. PubMed ID: 29098396
[TBL] [Abstract][Full Text] [Related]
74. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
Jahanzeb M
Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
[TBL] [Abstract][Full Text] [Related]
75. Male breast cancer is not congruent with the female disease.
Fentiman IS
Crit Rev Oncol Hematol; 2016 May; 101():119-24. PubMed ID: 26989051
[TBL] [Abstract][Full Text] [Related]
76. Hormonal therapy for male breast cancer: A different approach for a different disease.
Nahleh ZA
Cancer Treat Rev; 2006 Apr; 32(2):101-5. PubMed ID: 16472925
[TBL] [Abstract][Full Text] [Related]
77. [Aromatase inhibitors in the adjuvant treatment of early breast cancer. Is there still a place for tamoxifen?].
Bergerat JP
Presse Med; 2007 Feb; 36(2 Pt 2):333-40. PubMed ID: 17258683
[TBL] [Abstract][Full Text] [Related]
78. A review of the treatment of endocrine responsive metastatic breast cancer in postmenopausal women.
Cardoso F; Bischoff J; Brain E; Zotano ÁG; Lück HJ; Tjan-Heijnen VC; Tanner M; Aapro M
Cancer Treat Rev; 2013 Aug; 39(5):457-65. PubMed ID: 22840697
[TBL] [Abstract][Full Text] [Related]
79. Adjuvant therapy with aromatase inhibitors in postmenopausal, estrogen receptor- positive breast cancer patients: upfront or sequential?
Dediu M; Median D; Alexandru A; Vremes G; Gal C; Gongu M
J BUON; 2009; 14(3):375-9. PubMed ID: 19810126
[TBL] [Abstract][Full Text] [Related]
80.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
